(1S,9R)-Exatecan mesylate

Synonyms: (1S,9R)-DX8951f
(1S,9R)-Exatecan mesylate ((1S,9R)-DX8951f) 是一种非前药喜树碱衍生物,作为拓扑异构酶 I 抑制剂(IC50=0.975 μg/mL 小鼠和 0.82 μg/mL 人),它通过稳定酶-DNA 可切割复合物来阻断酶活性并诱导细胞凋亡 (apoptosis),不仅能有效抑制多种恶性肿瘤细胞的增殖和肿瘤生长,还可规避 P-糖蛋白介导的多药耐药性,因而被广泛应用于胰腺癌、肺癌、乳腺癌、白血病等多种癌症的临床前研究中,其手性异构体为 (1R,9R)-Exatecan mesylate (MS-H96188)。
产品编号: MS-B07407 纯度: 99.11% CAS No.: 2938875-54-6 分子式: C25H26FN3O7S 分子量: 531.55
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
3-5 天
50mg
询价
3-5 天
100mg
询价
询价
200mg
询价
询价
500mg
询价
询价

产品描述

(1S,9R)-Exatecan mesylate ((1S,9R)-DX8951f) 是一种非前药喜树碱衍生物,作为拓扑异构酶 I 抑制剂(IC50=0.975 μg/mL 小鼠和 0.82 μg/mL 人),它通过稳定酶-DNA 可切割复合物来阻断酶活性并诱导细胞凋亡 (apoptosis),不仅能有效抑制多种恶性肿瘤细胞的增殖和肿瘤生长,还可规避 P-糖蛋白介导的多药耐药性,因而被广泛应用于胰腺癌、肺癌、乳腺癌、白血病等多种癌症的临床前研究中,其手性异构体为 (1R,9R)-Exatecan mesylate (MS-H96188)。

生物实验数据

生物活性 (1S,9R)-Exatecan mesylate ((1S,9R)-DX8951f) is a non-prodrug camptothecin derivative that acts as a topoisomerase I inhibitor (IC50=0.975 μg/mL in mouse and 0.82 μg/mL in human), blocking enzyme activity and inducing apoptosis (apoptosis) by stabilizing the enzyme-DNA cleavable complex; it not only effectively inhibits the proliferation and tumor growth of various malignant tumor cells but also circumvents P-glycoprotein-mediated multidrug resistance, and is therefore widely used in preclinical studies of various cancers such as pancreatic cancer, lung cancer, breast cancer, and leukemia, with its chiral isomer being (1R,9R)-Exatecan mesylate (MS-H96188).
IC50 & Target

Camptothecins

 

体外研究
(In Vitro)

(1S,9R)-Exatecan (mesylate) (48 h exposure; additional 5 days culture post-exposure) 及其盐酸盐形式 DX-8951a 可在体外强效抑制 SUIT-2、KP-1N、SUIT-2/CPT-11 和 KP-1N/CPT-11 人胰腺癌细胞的生长,IC50 值为 0.079 至 0.69 ng/mL;与其他喜树碱类似物相比,其在 CPT-11 耐药细胞系中的交叉耐药性更低。
(1S,9R)-Exatecan (mesylate) (0.16-10 μg/mL; 10 min at 37°C) (tested as DX-8951a) 可抑制 SUIT-2 人胰腺癌细胞中的拓扑异构酶 I 活性,其 IC50 为 0.82 μg/mL,抑制效力比 SN-38 强 2.8 倍。
(1S,9R)-Exatecan (mesylate) (0.8-500 ng/mL; 24 h) (以 DX-8951a 形式测试) 可剂量依赖性地诱导人胰腺癌细胞系 SUIT-2 发生 DNA 片段化 (细胞凋亡的标志物),20 ng/mL 作用 24 h 后可观察到 60% 的片段化,且其活性强于 SN-38。
(1S,9R)-Exatecan (mesylate) (0.05 μg/mL; 24 h) (tested as DX-8951a) 可在 SUIT-2 人胰腺癌细胞中诱导凋亡性细胞死亡的形态学特征,包括染色质浓缩、核碎裂和细胞质空泡化。
(1S,9R)-Exatecan (mesylate) (Doses yielding GI50 values; 3 days post-drug addition) 可强效抑制 31 种人类癌细胞系及小鼠白血病 P388 细胞的增殖,总体平均 GI50 为 2.09 ng/mL,且效力优于对比化合物。
(1S,9R)-Exatecan (mesylate) (Doses yielding IC50 values) 可强效抑制 P388 细胞来源的拓扑异构酶 I 活性,其 IC50 为 0.975 μg/mL,且效力优于对比化合物。
(1S,9R)-Exatecan (mesylate) (Doses yielding GI50 values; 3 days post-drug addition) 对过表达 P-糖蛋白的 PC-6/VCR 细胞仍具有强细胞毒活性,可克服 P-糖蛋白介导的多药耐药性。

Apoptosis Analysis

Cell Line: SUIT-2
Concentration: 0.8-500 ng/mL
Incubation Time: 24 h
Result: Induced DNA fragmentation in a dose-dependent manner.
Caused approximately 60% DNA fragmentation at 20 ng/mL.
Achieved equivalent fragmentation at a 5-times lower concentration than SN-38.

Cell Cytotoxicity Assay

Cell Line: 31 human cancer cell lines (breast, colon, stomach, lung, ovarian, leukemia) and mouse leukemia P388 cells
Concentration: Doses yielding GI50 values
Incubation Time: 3 days post-drug addition
Result: Exhibited strong antiproliferative activity with mean GI50 values of 2.02 ng/mL against breast cancer cell lines, 2.92 ng/mL against colon cancer cell lines, 1.53 ng/mL against stomach cancer cell lines, 0.877 ng/mL against lung cancer cell lines, and 4.33 ng/mL against other cell lines including ovarian cancer, human leukemia, and mouse leukemia.
Achieved an overall mean GI50 value of 2.09 ng/mL across all 32 cell lines.

Cell Cytotoxicity Assay

Cell Line: Human non-small cell lung cancer PC-6 cells and its P-glycoprotein-overexpressing variant PC-6/VCR cells
Concentration: Doses yielding GI50 values; 5 μg/mL verapamil (co-treatment with PC-6/VCR cells)
Incubation Time: 3 days post-drug addition
Result: Achieved GI50 values of 0.0896 ng/mL for PC-6 cells and 0.0690 ng/mL for PC-6/VCR cells (without verapamil, first set), with a degree of resistance of 0.8.
Achieved GI50 values of 0.179 ng/mL for PC-6 cells and 0.182 ng/mL for PC-6/VCR cells (without verapamil, second set), with a degree of resistance of 1.0.
Reduced the GI50 value of PC-6/VCR cells to 0.156 ng/mL (with 5 μg/mL verapamil), with a VR (+)/VR (−) ratio of 0.86.
体内研究
(In Vivo)

(1S,9R)-Exatecan (mesylate) (3.125-18.75 mg/kg; i.v.; every 4 days; 4 doses) 在裸鼠的 SUIT-2 胰腺癌异种移植物模型中,可在较宽剂量范围内产生具有统计学意义的肿瘤生长抑制作用,抑制率为 68% 至 79%,且未出现相关的体重减轻或毒性相关死亡。
(1S,9R)-Exatecan (mesylate) (3.125-18.75 mg/kg; i.v.; every 4 days; 4 doses) 在最大耐受剂量下,对裸鼠体内耐 CPT-11 的 SUIT-2/CPT-11 胰腺癌异种移植物产生 72%的具有统计学意义的肿瘤生长抑制作用,仅出现短暂的体重下降,且无毒性相关死亡。
(1S,9R)-Exatecan (mesylate) (2.5-10 mg/kg; i.v.; every 5 days; 4 doses) 可在裸鼠中对 SUIT-2 胰腺癌的肝转移产生剂量依赖性、具有统计学意义的抑制作用;在最高测试剂量下,肝肿瘤评分抑制率达 78%,且 7 只小鼠中有 3 只无瘤,同时未出现显著的体重下降。
(1S,9R)-Exatecan (mesylate) (3.325-50 mg/kg; i.v.; three doses at 4-day intervals) 对裸鼠体内人胃腺癌 SC-6 异种移植物表现出剂量依赖性的强效抗肿瘤活性;在总静脉注射剂量为 50 mg/kg (three doses at 4-day intervals) 时,其对肿瘤生长的最大体重抑制率达 92%,且未导致动物中毒死亡。

Animal Model: BALB/c-nu/nu (male, 6 weeks old)
Dosage: 3.125 mg/kg (total 12.5 mg/kg); 6.25 mg/kg (total 25 mg/kg); 12.5 mg/kg (total 50 mg/kg); 18.75 mg/kg (total 75 mg/kg)
Administration: i.v.; every 4 days; 4 doses
Result: Produced tumor growth inhibition (IR) rates of 68%, 78%, 68%, and 79%, respectively.
Resulted in mean tumor weights of 0.235±0.057 g, 0.164±0.053 g, 0.236±0.100 g, and 0.154±0.027 g, respectively.
Caused no body weight loss in any treated group, and no mice died of toxicity.\nAt total dose of 75 mg/kg, produced a tumor growth inhibition (IR) rate of 72% with a mean tumor weight of 0.250±0.061 g; caused maximum body weight loss of 14.6% on day 31.
At total doses of 50 mg/kg, 25 mg/kg, and 12.5 mg/kg, resulted in IR rates of 33%, 13%, and 20% with mean tumor weights of 0.595±0.130 g, 0.776±0.157 g, and 0.712±0.065 g, respectively; caused maximum body weight loss of 6.1% (day 21), 8.7% (day 15), and 3.2% (day 15), respectively.
Caused no mice to die of toxicity in any treated group.
Animal Model: BALB/c-nu/nu (male, 6 weeks old)
Dosage: 2.5 mg/kg (total 10 mg/kg); 5 mg/kg (total 20 mg/kg); 10 mg/kg (total 40 mg/kg)
Administration: i.v.; every 5 days; 4 doses
Result: At total dose of 40 mg/kg, produced a liver tumor growth score inhibition rate of 78%, with a mean liver tumor score of 0.7±0.9, mean liver weight of 1.594±0.154 g, and 3/7 mice with no visible liver tumor nodules; found 2/7 mice with visible spleen tumor nodules, and 0/7 mice with ascites, with 3/7 mice being tumor-free.
At total dose of 20 mg/kg, resulted in a liver tumor growth score inhibition rate of 69%, with a mean liver tumor score of 1.0±0.6, mean liver weight of 1.594±0.163 g, 5/6 mice with liver tumor nodules, 2/6 mice with spleen tumor nodules, 0/6 mice with ascites, and 1/6 mice tumor-free.
At total dose of 10 mg/kg, resulted in a liver tumor growth score inhibition rate of 28%, with a mean liver tumor score of 2.3±1.1, mean liver weight of 1.780±0.197 g, 6/6 mice with liver tumor nodules, 3/6 mice with spleen tumor nodules, 2/6 mice with ascites (mean volume 0.1±0.1 mL, 97% inhibition), and 0/6 mice tumor-free.
Caused no significant body weight loss.
Animal Model: BALB/c-nu/nu (male, 5 or 6 weeks old, human gastric adenocarcinoma SC-6 cells transplanted s.c.)
Dosage: 3.325 mg/kg; 6.25 mg/kg; 12.5 mg/kg; 25 mg/kg; 50 mg/kg
Administration: i.v.; three doses at 4-day intervals
Result: Achieved 54% maximal tumor growth inhibition by volume (day 12) and 43% tumor growth inhibition by weight at total dose 3.325 mg/kg, with 3.8% maximal body weight reduction (day 6) and 0 toxic deaths.
Achieved 72% maximal tumor growth inhibition by volume (day 14) and 58% statistically significant tumor growth inhibition by weight at total dose 6.25 mg/kg, with 2.6% maximal body weight reduction (day 6) and 0 toxic deaths.
Achieved 82% maximal tumor growth inhibition by volume (day 17) and 73% statistically significant tumor growth inhibition by weight at total dose 12.5 mg/kg, with 5.9% maximal body weight reduction (day 6) and 0 toxic deaths.
Achieved 95% maximal tumor growth inhibition by volume (day 17) and 90% statistically significant tumor growth inhibition by weight at total dose 25 mg/kg, with 7.0% maximal body weight reduction (day 6) and 0 toxic deaths.
Achieved 96% maximal tumor growth inhibition by volume (day 17) and 92% statistically significant tumor growth inhibition by weight at total dose 50 mg/kg, with 12.5% maximal body weight reduction (day 12) and 0 toxic deaths.
性状 固体
颜色 White to yellow

化学信息

分子量 531.55
分子式 C25H26FN3O7S
CAS No. 2938875-54-6
别名 (1S,9R)-DX8951f

储存&溶解度

储存方式

4°C, sealed storage, away from moisture and light

*In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 50 mg/mL (94.06 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM1.8813 mL9.4065 mL18.8129 mL47.0323 mL
5 mM0.3763 mL1.8813 mL3.7626 mL9.4065 mL
10 mM0.1881 mL0.9406 mL1.8813 mL4.7032 mL
15 mM0.1254 mL0.6271 mL1.2542 mL3.1355 mL
20 mM0.0941 mL0.4703 mL0.9406 mL2.3516 mL
25 mM0.0753 mL0.3763 mL0.7525 mL1.8813 mL
30 mM0.0627 mL0.3135 mL0.6271 mL1.5677 mL
40 mM0.0470 mL0.2352 mL0.4703 mL1.1758 mL
50 mM0.0376 mL0.1881 mL0.3763 mL0.9406 mL
60 mM0.0314 mL0.1568 mL0.3135 mL0.7839 mL
80 mM0.0235 mL0.1176 mL0.2352 mL0.5879 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础